Pharma Veterans

Status of Pharmaceutical Business in Pakistan 2024 – Part II – Asrar Qureshi’s Blog Post 962 Dear Colleagues! This is Asrar Qureshi’s Blog Post 962 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to aq.pharmaveterans@gmail.com for publishing your contributions here. Credit: Kübra Kuzu Credit: Polina Tankilevitch Credit: Tran Nhu Tuan This is the second and last part. Corporates Growth Pakistan market is extremely unevenly divided with about 95% market share with only top 100 companies. The top players added further huge revenues to their already bursting volumes. They have also further strengthened their positions by increasing share of the total market. The top players have done this by growing at a rate higher than the market growth. How are they able to do it? There are several factors. Human Resource – The big players have the financial strength and market standing to attract top talent. Once a

Policies - Compliance - Culture – Asrar Qureshi’s Blog Post #839 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #839 for Pharma Veterans. Pharma Veterans aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Elizabeth Holmes - CEO Theranos Pfizer gabapentin Pharmaceutical industry is regarded as a highly regulated industry and rightly so. At every step, regulations are applied. The data generated during production and quality control is religiously documented and vetted at various levels. Research data is subjected to even more rigorous vetting. When the local or international teams visit for inspection, their main emphasis is on reviewing documents. The process is simple; they ask for SOPs, review these, and then ask for compliance reports. Compliance becomes the key parameter because

 Drug Development Update – Asrar Qureshi’s Blog Post #837 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #837 for Pharma Veterans. Pharma Veterans aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Photo Credit: Pavel Danilyuk Photo Credit: Pixabay Photo Credit: RF._. studio Periodically, I bring to you the update on new registrations by the USFDA. USFDA approval is most relevant because most research is happening in the US, and USFDA is mostly the first regulatory authority to approve new drugs, line extensions, new combinations, and expansion of indications. Some drugs are first applied to EMA – European Medicines Agency, but these are relatively few.  A look at new approvals is not just academic; it shows where the research is going, and where most investment is being done. It als

Pakistan Pharma Industry SWOT – Part 5 – Asrar Qureshi’s Blog Post #596 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #596 for Pharma Veterans. Pharma Veterans welcome sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Opening Note February 2022  marks my completing 47 years of working in Pharma Industry. Allah be praised. I am still working. The first half of my working career was spent in Multinational companies, and the latter half in the Local Pharma, making me well-versed with both innovators and generics markets. I also had the opportunity to work in business as well as operations.  My journey of near half century is also the journey of Pharma Industry in Pakistan. Great changes have occurred in this time and a lot could be written about it. In my blogs, which were started about fou